__label__noRel	The overall remission rate was 87% with 31% complete remissions.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__Support	The overall remission rate was 87% with 31% complete remissions.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__Support	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__Support	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__Support	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__Support	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__Support	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__Support	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	CP resulted in more anastomotic leaks.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	CP resulted in more anastomotic leaks.
__label__Support	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	CP resulted in more anastomotic leaks.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__Support	there were no differences in the bowel function, continence score, and quality of life at 1 year.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	CP resulted in more anastomotic leaks.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	CP resulted in more anastomotic leaks.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	CP resulted in more anastomotic leaks.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	CP resulted in more anastomotic leaks.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	CP resulted in more anastomotic leaks.
__label__noRel	CP resulted in more anastomotic leaks.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	CP resulted in more anastomotic leaks.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	CP resulted in more anastomotic leaks.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	CP resulted in more anastomotic leaks.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	CP resulted in more anastomotic leaks.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__Support	CP resulted in more anastomotic leaks.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	CP resulted in more anastomotic leaks.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	CP resulted in more anastomotic leaks.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Attack	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__Attack	but these were not associated with increased hospital admissions, infections or fatalities.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__Support	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__Support	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	There is a need for further studies so that its effect can be confirmed.
__label__Support	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	There is a need for further studies so that its effect can be confirmed.
__label__Support	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	There is a need for further studies so that its effect can be confirmed.
__label__Support	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	There is a need for further studies so that its effect can be confirmed.
__label__Attack	There is a need for further studies so that its effect can be confirmed.	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	There is a need for further studies so that its effect can be confirmed.	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	There is a need for further studies so that its effect can be confirmed.	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	There is a need for further studies so that its effect can be confirmed.	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__Support	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	but there were positive changes in group A patients.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	but there were positive changes in group A patients.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	but there were positive changes in group A patients.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	but there were positive changes in group A patients.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	but there were positive changes in group A patients.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	but there were positive changes in group A patients.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	but there were positive changes in group A patients.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	but there were positive changes in group A patients.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	but there were positive changes in group A patients.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	but there were positive changes in group A patients.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	but there were positive changes in group A patients.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	but there were positive changes in group A patients.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	but there were positive changes in group A patients.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	but there were positive changes in group A patients.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	but there were positive changes in group A patients.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	but there were positive changes in group A patients.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	but there were positive changes in group A patients.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	but there were positive changes in group A patients.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	the between-group difference was statistically significant (P<0.01).
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	the between-group difference was statistically significant (P<0.05).
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	the between-group difference was statistically significant (P<0.01).
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	the between-group difference was statistically significant (P<0.05).
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__Support	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	the between-group difference was statistically significant (P<0.01).	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__Support	the between-group difference was statistically significant (P<0.01).	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.01).	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.01).	the between-group difference was statistically significant (P<0.05).
__label__noRel	the between-group difference was statistically significant (P<0.01).	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	the between-group difference was statistically significant (P<0.01).	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	the between-group difference was statistically significant (P<0.01).	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	the between-group difference was statistically significant (P<0.01).
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	the between-group difference was statistically significant (P<0.05).
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__Support	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	the between-group difference was statistically significant (P<0.05).	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	the between-group difference was statistically significant (P<0.05).	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.05).	the between-group difference was statistically significant (P<0.01).
__label__Support	the between-group difference was statistically significant (P<0.05).	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.05).	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	the between-group difference was statistically significant (P<0.05).	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	the between-group difference was statistically significant (P<0.05).	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	the between-group difference was statistically significant (P<0.01).
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	the between-group difference was statistically significant (P<0.05).
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__Support	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	the between-group difference was statistically significant (P<0.01).
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	the between-group difference was statistically significant (P<0.05).
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__Support	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	the between-group difference was statistically significant (P<0.01).
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	the between-group difference was statistically significant (P<0.05).
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	Most patients with advanced ovarian cancer develop recurrent disease.
__label__Attack	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__Support	No statistically significant differences in quality of life scores between arms were noted.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	Safe, effective non-hormonal treatments are needed.
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -1·67, 95% CI -2·43 to -0·91; p<0·0001) and improvements were maintained at 26 weeks (mean difference -1·76, -2·54 to -0·99; p<0·0001).
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	We recorded no CBT-related adverse events.
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	Safe, effective non-hormonal treatments are needed.	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	Safe, effective non-hormonal treatments are needed.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -1·67, 95% CI -2·43 to -0·91; p<0·0001) and improvements were maintained at 26 weeks (mean difference -1·76, -2·54 to -0·99; p<0·0001).
__label__noRel	Safe, effective non-hormonal treatments are needed.	We recorded no CBT-related adverse events.
__label__noRel	Safe, effective non-hormonal treatments are needed.	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -1·67, 95% CI -2·43 to -0·91; p<0·0001) and improvements were maintained at 26 weeks (mean difference -1·76, -2·54 to -0·99; p<0·0001).	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -1·67, 95% CI -2·43 to -0·91; p<0·0001) and improvements were maintained at 26 weeks (mean difference -1·76, -2·54 to -0·99; p<0·0001).	Safe, effective non-hormonal treatments are needed.
__label__noRel	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -1·67, 95% CI -2·43 to -0·91; p<0·0001) and improvements were maintained at 26 weeks (mean difference -1·76, -2·54 to -0·99; p<0·0001).	We recorded no CBT-related adverse events.
__label__Support	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -1·67, 95% CI -2·43 to -0·91; p<0·0001) and improvements were maintained at 26 weeks (mean difference -1·76, -2·54 to -0·99; p<0·0001).	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	We recorded no CBT-related adverse events.	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	We recorded no CBT-related adverse events.	Safe, effective non-hormonal treatments are needed.
__label__noRel	We recorded no CBT-related adverse events.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -1·67, 95% CI -2·43 to -0·91; p<0·0001) and improvements were maintained at 26 weeks (mean difference -1·76, -2·54 to -0·99; p<0·0001).
__label__Support	We recorded no CBT-related adverse events.	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	Safe, effective non-hormonal treatments are needed.
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -1·67, 95% CI -2·43 to -0·91; p<0·0001) and improvements were maintained at 26 weeks (mean difference -1·76, -2·54 to -0·99; p<0·0001).
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	We recorded no CBT-related adverse events.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	The quality of life was almost the same between the arms
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The quality of life was almost the same between the arms
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	The quality of life was almost the same between the arms
__label__Support	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The quality of life was almost the same between the arms
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__Support	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The quality of life was almost the same between the arms
__label__Support	Grades 3/4 toxicities occurred infrequently in both arms.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	The quality of life was almost the same between the arms	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	The quality of life was almost the same between the arms	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The quality of life was almost the same between the arms	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	The quality of life was almost the same between the arms	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The quality of life was almost the same between the arms	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The quality of life was almost the same between the arms	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The quality of life was almost the same between the arms	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The quality of life was almost the same between the arms
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The quality of life was almost the same between the arms
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.
__label__noRel	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.
__label__Support	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.
__label__noRel	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).
__label__noRel	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.
__label__Support	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.
__label__Attack	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).
__label__noRel	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.
__label__noRel	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.
__label__noRel	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).
__label__noRel	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.
__label__noRel	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	No decrease in fatigue-related distress was detected.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	No decrease in fatigue-related distress was detected.
__label__Support	The intervention demonstrated a trend toward improved CRF,	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__Attack	although this effect was reduced once confounders had been controlled statistically.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	No decrease in fatigue-related distress was detected.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	No decrease in fatigue-related distress was detected.
__label__Support	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	No decrease in fatigue-related distress was detected.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	No decrease in fatigue-related distress was detected.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	No decrease in fatigue-related distress was detected.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	No decrease in fatigue-related distress was detected.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__Support	No decrease in fatigue-related distress was detected.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	No decrease in fatigue-related distress was detected.
__label__noRel	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).
__label__noRel	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.
__label__Support	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.
__label__noRel	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.
__label__Support	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.
__label__noRel	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__Attack	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__Support	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	at no point was any significant difference apparent on this end point.
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	Both treatments led to an improvement, over time, in dyspnoea.
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	at no point was any significant difference apparent on this end point.
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	Both treatments led to an improvement, over time, in dyspnoea.
__label__Support	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	at no point was any significant difference apparent on this end point.
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	Both treatments led to an improvement, over time, in dyspnoea.
__label__Support	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	at no point was any significant difference apparent on this end point.	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	at no point was any significant difference apparent on this end point.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__Support	at no point was any significant difference apparent on this end point.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	at no point was any significant difference apparent on this end point.	Both treatments led to an improvement, over time, in dyspnoea.
__label__noRel	at no point was any significant difference apparent on this end point.	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	at no point was any significant difference apparent on this end point.	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	at no point was any significant difference apparent on this end point.	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	at no point was any significant difference apparent on this end point.
__label__Support	Both treatments led to an improvement, over time, in dyspnoea.	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	Both treatments led to an improvement, over time, in dyspnoea.	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	at no point was any significant difference apparent on this end point.
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	Both treatments led to an improvement, over time, in dyspnoea.
__label__noRel	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__Support	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	at no point was any significant difference apparent on this end point.
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	Both treatments led to an improvement, over time, in dyspnoea.
__label__Attack	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	For malignant pleural mesothelioma (MPM) patients with a poor prognosis, maintaining health-related quality of life (HRQOL) is important.
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	The clinical results found raltitrexed and cisplatin to be superior to cisplatin with regard to overall survival (P = .048).
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	The global HRQOL scale was comparable at baseline on both treatment arms (P = .848);
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	at no point was any significant difference apparent on this end point.
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	Both treatments led to an improvement, over time, in dyspnoea.
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	This effect is an important clinically meaningful reduction from baseline in the cisplatin/raltitrexed arm.
__label__noRel	This study provides important information about the HRQOL of chemotherapy-treated MPM patients.	However, the majority of scales of the EORTC QLQ-C30 or LC13 showed stabilization of HRQOL with few clinically significant differences between the treatment arms.
__label__noRel	No adverse events or skeletal complications occurred during the supervised exercise sessions.	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5).
__label__noRel	No adverse events or skeletal complications occurred during the supervised exercise sessions.	The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.
__label__noRel	No adverse events or skeletal complications occurred during the supervised exercise sessions.	No significant between-group differences were observed for fatigue, quality of life or psychological distress.
__label__Support	No adverse events or skeletal complications occurred during the supervised exercise sessions.	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.
__label__noRel	No adverse events or skeletal complications occurred during the supervised exercise sessions.	Future trials involving larger sample sizes are required to expand these preliminary findings.
__label__noRel	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5).	No adverse events or skeletal complications occurred during the supervised exercise sessions.
__label__noRel	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5).	The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.
__label__noRel	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5).	No significant between-group differences were observed for fatigue, quality of life or psychological distress.
__label__Support	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5).	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.
__label__noRel	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5).	Future trials involving larger sample sizes are required to expand these preliminary findings.
__label__noRel	The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.	No adverse events or skeletal complications occurred during the supervised exercise sessions.
__label__noRel	The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5).
__label__noRel	The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.	No significant between-group differences were observed for fatigue, quality of life or psychological distress.
__label__Support	The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.
__label__noRel	The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.	Future trials involving larger sample sizes are required to expand these preliminary findings.
__label__noRel	No significant between-group differences were observed for fatigue, quality of life or psychological distress.	No adverse events or skeletal complications occurred during the supervised exercise sessions.
__label__noRel	No significant between-group differences were observed for fatigue, quality of life or psychological distress.	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5).
__label__noRel	No significant between-group differences were observed for fatigue, quality of life or psychological distress.	The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.
__label__Support	No significant between-group differences were observed for fatigue, quality of life or psychological distress.	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.
__label__noRel	No significant between-group differences were observed for fatigue, quality of life or psychological distress.	Future trials involving larger sample sizes are required to expand these preliminary findings.
__label__noRel	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.	No adverse events or skeletal complications occurred during the supervised exercise sessions.
__label__noRel	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5).
__label__noRel	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.	The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.
__label__noRel	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.	No significant between-group differences were observed for fatigue, quality of life or psychological distress.
__label__noRel	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.	Future trials involving larger sample sizes are required to expand these preliminary findings.
__label__noRel	Future trials involving larger sample sizes are required to expand these preliminary findings.	No adverse events or skeletal complications occurred during the supervised exercise sessions.
__label__noRel	Future trials involving larger sample sizes are required to expand these preliminary findings.	The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5).
__label__noRel	Future trials involving larger sample sizes are required to expand these preliminary findings.	The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group.
__label__noRel	Future trials involving larger sample sizes are required to expand these preliminary findings.	No significant between-group differences were observed for fatigue, quality of life or psychological distress.
__label__Attack	Future trials involving larger sample sizes are required to expand these preliminary findings.	This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass.
__label__noRel	No late arising QOL issues were observed.	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	No late arising QOL issues were observed.	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	No late arising QOL issues were observed.	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	No late arising QOL issues were observed.	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__Support	No late arising QOL issues were observed.	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__noRel	No late arising QOL issues were observed.	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	No late arising QOL issues were observed.
__label__noRel	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__Support	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__noRel	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	No late arising QOL issues were observed.
__label__noRel	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__Support	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__noRel	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	No late arising QOL issues were observed.
__label__noRel	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__noRel	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__Support	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	No late arising QOL issues were observed.
__label__noRel	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__Support	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	No late arising QOL issues were observed.
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__noRel	In this randomized trial, no long-term QOL advantage for either treatment was apparent	with the exception of poorer sexual function reported by those treated with cryoablation.
__label__noRel	with the exception of poorer sexual function reported by those treated with cryoablation.	No late arising QOL issues were observed.
__label__noRel	with the exception of poorer sexual function reported by those treated with cryoablation.	Regardless of treatment arm, participants reported high levels of QOL with few exceptions.
__label__noRel	with the exception of poorer sexual function reported by those treated with cryoablation.	cryoablation was associated with more acute urinary dysfunction (mean PCI urinary function cryoablation=69.4; mean EBRT=90.7; P<.001), which resolved over time.
__label__noRel	with the exception of poorer sexual function reported by those treated with cryoablation.	Both EBRT and cryoablation participants reported decreases in sexual function at 3 months with the cryoablation patients reporting poorer functioning (mean cryoablation=7.2: mean EBRT=32.9; P<.001).
__label__noRel	with the exception of poorer sexual function reported by those treated with cryoablation.	Mean sexual function score was 15 points lower at 3 years for the cryoablation group and 13% more of the cryoablation men said that sexuality was a moderate or big problem.
__label__Attack	with the exception of poorer sexual function reported by those treated with cryoablation.	In this randomized trial, no long-term QOL advantage for either treatment was apparent
__label__noRel	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.	a significant reduction (p < 0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.
__label__noRel	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.	Results analysis revealed that OMWQ-HN (F = 12.199, df = 6,1314, p < 0.001) and FACT-HN (p < 0.05) scores were significantly lower in LLLT than placebo group patients.
__label__Support	a significant reduction (p < 0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.
__label__noRel	a significant reduction (p < 0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.	Results analysis revealed that OMWQ-HN (F = 12.199, df = 6,1314, p < 0.001) and FACT-HN (p < 0.05) scores were significantly lower in LLLT than placebo group patients.
__label__Support	Results analysis revealed that OMWQ-HN (F = 12.199, df = 6,1314, p < 0.001) and FACT-HN (p < 0.05) scores were significantly lower in LLLT than placebo group patients.	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.
__label__noRel	Results analysis revealed that OMWQ-HN (F = 12.199, df = 6,1314, p < 0.001) and FACT-HN (p < 0.05) scores were significantly lower in LLLT than placebo group patients.	a significant reduction (p < 0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.
__label__noRel	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2 ± 5.2 kcal/kg/day vs 12.7 ± 3.4 kcal/kg/day [P = .001] and 6.2 ± 0.9 vs 4.1 ± 0.9 [P < .0001], respectively).
__label__noRel	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.
__label__noRel	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.
__label__noRel	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.
__label__noRel	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2 ± 5.2 kcal/kg/day vs 12.7 ± 3.4 kcal/kg/day [P = .001] and 6.2 ± 0.9 vs 4.1 ± 0.9 [P < .0001], respectively).	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.
__label__noRel	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2 ± 5.2 kcal/kg/day vs 12.7 ± 3.4 kcal/kg/day [P = .001] and 6.2 ± 0.9 vs 4.1 ± 0.9 [P < .0001], respectively).	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.
__label__noRel	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2 ± 5.2 kcal/kg/day vs 12.7 ± 3.4 kcal/kg/day [P = .001] and 6.2 ± 0.9 vs 4.1 ± 0.9 [P < .0001], respectively).	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.
__label__Support	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2 ± 5.2 kcal/kg/day vs 12.7 ± 3.4 kcal/kg/day [P = .001] and 6.2 ± 0.9 vs 4.1 ± 0.9 [P < .0001], respectively).	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.
__label__noRel	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.
__label__noRel	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2 ± 5.2 kcal/kg/day vs 12.7 ± 3.4 kcal/kg/day [P = .001] and 6.2 ± 0.9 vs 4.1 ± 0.9 [P < .0001], respectively).
__label__noRel	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.
__label__Support	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.
__label__noRel	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.
__label__noRel	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2 ± 5.2 kcal/kg/day vs 12.7 ± 3.4 kcal/kg/day [P = .001] and 6.2 ± 0.9 vs 4.1 ± 0.9 [P < .0001], respectively).
__label__noRel	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.
__label__Support	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.
__label__noRel	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.	Cisplatin reduces plasma ghrelin levels through the 5-hydroxytryptamine (5-HT) receptor.
__label__noRel	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.	Food intake and appetite VAS scores were significantly higher in the ghrelin group than in the placebo group (18.2 ± 5.2 kcal/kg/day vs 12.7 ± 3.4 kcal/kg/day [P = .001] and 6.2 ± 0.9 vs 4.1 ± 0.9 [P < .0001], respectively).
__label__noRel	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.	Patients in the ghrelin group had fewer adverse events during chemotherapy related to anorexia and nausea than patients in the control group.
__label__noRel	Short-term administration of exogenous ghrelin at the start of cisplatin-based chemotherapy stimulated food intake and minimized adverse events.	Significant deterioration was noted after chemotherapy in the placebo group in QoL scores, appetite, nausea and vomiting, and global health status.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	They deteriorated during follow-up in women not continuing ccHRT.
__label__Support	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	They deteriorated during follow-up in women not continuing ccHRT.
__label__Support	Climacteric symptoms remained significantly below baseline values after dosage reduction;	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	Climacteric symptoms remained significantly below baseline values after dosage reduction;	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	They deteriorated during follow-up in women not continuing ccHRT.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	some symptoms recurred after discontinuation of ccHRT.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	They deteriorated during follow-up in women not continuing ccHRT.
__label__Support	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	They deteriorated during follow-up in women not continuing ccHRT.
__label__Support	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	They deteriorated during follow-up in women not continuing ccHRT.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	They deteriorated during follow-up in women not continuing ccHRT.
__label__noRel	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__Support	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	They deteriorated during follow-up in women not continuing ccHRT.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.	This supports the need for an individualized approach to therapy recommendations.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	Climacteric symptoms remained significantly below baseline values after dosage reduction;
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	some symptoms recurred after discontinuation of ccHRT.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	They deteriorated during follow-up in women not continuing ccHRT.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
__label__noRel	This supports the need for an individualized approach to therapy recommendations.	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
__label__noRel	HRQOL and symptom relief were equivalent in the treatment arms.	No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively.
__label__Support	HRQOL and symptom relief were equivalent in the treatment arms.	Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC.
__label__noRel	No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively.	HRQOL and symptom relief were equivalent in the treatment arms.
__label__Support	No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively.	Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC.
__label__noRel	Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC.	HRQOL and symptom relief were equivalent in the treatment arms.
__label__noRel	Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC.	No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively.
__label__noRel	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.
__label__Support	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.
__label__noRel	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).	Newly available angiogenesis inhibitors should be preferred for these patients.
__label__noRel	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).
__label__Support	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.
__label__noRel	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.	Newly available angiogenesis inhibitors should be preferred for these patients.
__label__noRel	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).
__label__noRel	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.
__label__Support	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.	Newly available angiogenesis inhibitors should be preferred for these patients.
__label__noRel	Newly available angiogenesis inhibitors should be preferred for these patients.	There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively).
__label__noRel	Newly available angiogenesis inhibitors should be preferred for these patients.	Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients.
__label__noRel	Newly available angiogenesis inhibitors should be preferred for these patients.	Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity.
__label__noRel	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.
__label__Support	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.
__label__noRel	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).	Sexual functioning and symptoms did not differ between the treatment groups.
__label__noRel	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).
__label__Support	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.
__label__noRel	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.	Sexual functioning and symptoms did not differ between the treatment groups.
__label__noRel	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).
__label__noRel	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.
__label__noRel	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.	Sexual functioning and symptoms did not differ between the treatment groups.
__label__noRel	Sexual functioning and symptoms did not differ between the treatment groups.	Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001).
__label__noRel	Sexual functioning and symptoms did not differ between the treatment groups.	Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms.
__label__Support	Sexual functioning and symptoms did not differ between the treatment groups.	Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.
__label__noRel	Baseline characteristics were comparable for both groups,	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	Baseline characteristics were comparable for both groups,	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	Baseline characteristics were comparable for both groups,	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	Baseline characteristics were comparable for both groups,	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__noRel	Baseline characteristics were comparable for both groups,	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__Attack	except that more patients with ADPKD were assigned to the placebo group (P = .03).	Baseline characteristics were comparable for both groups,
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	Baseline characteristics were comparable for both groups,
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__Support	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	Baseline characteristics were comparable for both groups,
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__Support	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	Baseline characteristics were comparable for both groups,
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__Support	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	Baseline characteristics were comparable for both groups,
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__noRel	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__noRel	At 6 weeks, both groups showed improvement in several HQL domains,	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	At 6 weeks, both groups showed improvement in several HQL domains,	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	At 6 weeks, both groups showed improvement in several HQL domains,	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	At 6 weeks, both groups showed improvement in several HQL domains,	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	At 6 weeks, both groups showed improvement in several HQL domains,	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__Support	At 6 weeks, both groups showed improvement in several HQL domains,	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__noRel	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__Support	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__noRel	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__Support	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__noRel	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__Support	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__Support	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
__label__Support	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
__label__noRel	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	At 6 weeks, both groups showed improvement in several HQL domains,
__label__noRel	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
__label__noRel	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
__label__noRel	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
__label__noRel	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__noRel	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__noRel	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__Support	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__noRel	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__Support	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__noRel	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__Support	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__Attack	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__Attack	Although the CR/PR and SD(6m) groups had similar times to treatment failure,	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m)).
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	responders indicated better physical well-being (P =. 004) and mood (P =.02) at month 3.
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	Compared only with patients with SD(6m), responders showed no significant difference in baseline QL and time to treatment failure (328.5 v 340 days).
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	While under treatment, responders reported significantly better physical well-being (months 3 to 11), mood (months 5 to 11), coping (months 5 to 9), and appetite (months 7 to 11) and less dizziness (month 9) than patients with SD(6m).
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	The changes between baseline and months 5 and 7, respectively, indicated improvement in responders but heterogeneous patterns in patients with SD(6m).
__label__noRel	patients with CR/PR reported better QL, suggesting more beneficial response to second-line endocrine treatment.	Although the CR/PR and SD(6m) groups had similar times to treatment failure,
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	We found no difference in follow-up costs.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__Support	Food intake improved more rapidly after stent placement than after GJJ,	Medical effects were better after GJJ
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	although GJJ had higher total costs.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ,	Since the cost difference between the two treatments was only small,
__label__Attack	but long-term relief of obstructive symptoms was better after GJJ.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	We found no difference in follow-up costs.
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	Medical effects were better after GJJ
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	although GJJ had higher total costs.
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	but long-term relief of obstructive symptoms was better after GJJ.	Since the cost difference between the two treatments was only small,
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	We found no difference in follow-up costs.
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__Support	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	Medical effects were better after GJJ
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	although GJJ had higher total costs.
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.	Since the cost difference between the two treatments was only small,
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	We found no difference in follow-up costs.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	Medical effects were better after GJJ
__label__Support	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	although GJJ had higher total costs.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).	Since the cost difference between the two treatments was only small,
__label__noRel	We found no difference in follow-up costs.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	We found no difference in follow-up costs.	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	We found no difference in follow-up costs.	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	We found no difference in follow-up costs.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	We found no difference in follow-up costs.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	We found no difference in follow-up costs.	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	We found no difference in follow-up costs.	Medical effects were better after GJJ
__label__Support	We found no difference in follow-up costs.	although GJJ had higher total costs.
__label__noRel	We found no difference in follow-up costs.	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	We found no difference in follow-up costs.	Since the cost difference between the two treatments was only small,
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	We found no difference in follow-up costs.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	Medical effects were better after GJJ
__label__Support	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	although GJJ had higher total costs.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).	Since the cost difference between the two treatments was only small,
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	We found no difference in follow-up costs.
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	Medical effects were better after GJJ
__label__Support	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	although GJJ had higher total costs.
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.	Since the cost difference between the two treatments was only small,
__label__noRel	Medical effects were better after GJJ	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	Medical effects were better after GJJ	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	Medical effects were better after GJJ	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	Medical effects were better after GJJ	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	Medical effects were better after GJJ	We found no difference in follow-up costs.
__label__noRel	Medical effects were better after GJJ	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	Medical effects were better after GJJ	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	Medical effects were better after GJJ	although GJJ had higher total costs.
__label__noRel	Medical effects were better after GJJ	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	Medical effects were better after GJJ	Since the cost difference between the two treatments was only small,
__label__noRel	although GJJ had higher total costs.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	although GJJ had higher total costs.	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	although GJJ had higher total costs.	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	although GJJ had higher total costs.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	although GJJ had higher total costs.	We found no difference in follow-up costs.
__label__noRel	although GJJ had higher total costs.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	although GJJ had higher total costs.	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	although GJJ had higher total costs.	Medical effects were better after GJJ
__label__noRel	although GJJ had higher total costs.	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	although GJJ had higher total costs.	Since the cost difference between the two treatments was only small,
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	We found no difference in follow-up costs.
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	Medical effects were better after GJJ
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	although GJJ had higher total costs.
__label__noRel	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.	Since the cost difference between the two treatments was only small,
__label__noRel	Since the cost difference between the two treatments was only small,	Food intake improved more rapidly after stent placement than after GJJ,
__label__noRel	Since the cost difference between the two treatments was only small,	but long-term relief of obstructive symptoms was better after GJJ.
__label__noRel	Since the cost difference between the two treatments was only small,	More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ.
__label__noRel	Since the cost difference between the two treatments was only small,	Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001).
__label__noRel	Since the cost difference between the two treatments was only small,	We found no difference in follow-up costs.
__label__noRel	Since the cost difference between the two treatments was only small,	Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049).
__label__noRel	Since the cost difference between the two treatments was only small,	The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
__label__noRel	Since the cost difference between the two treatments was only small,	Medical effects were better after GJJ
__label__noRel	Since the cost difference between the two treatments was only small,	although GJJ had higher total costs.
__label__Support	Since the cost difference between the two treatments was only small,	cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO.
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	All procedures were well tolerated by the patients.
__label__Support	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	All procedures were well tolerated by the patients.
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	All procedures were well tolerated by the patients.
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	All procedures were well tolerated by the patients.
__label__Support	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	All procedures were well tolerated by the patients.
__label__Support	There was no significant difference in grade III/IV adverse events between the two groups.	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	There was no significant difference in grade III/IV adverse events between the two groups.	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	All procedures were well tolerated by the patients.	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	All procedures were well tolerated by the patients.	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	All procedures were well tolerated by the patients.	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	All procedures were well tolerated by the patients.	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	All procedures were well tolerated by the patients.	There was no significant difference in grade III/IV adverse events between the two groups.
__label__Support	All procedures were well tolerated by the patients.	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	All procedures were well tolerated by the patients.	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	All procedures were well tolerated by the patients.	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	All procedures were well tolerated by the patients.	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	All procedures were well tolerated by the patients.
__label__Support	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	All procedures were well tolerated by the patients.
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	All procedures were well tolerated by the patients.
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01).
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05).
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01).
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01).
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	There was no significant difference in grade III/IV adverse events between the two groups.
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	All procedures were well tolerated by the patients.
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE.
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.
__label__noRel	Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid.	Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC).
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	Trends observed for the treatment groups were similar.
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	the change did not meet the clinically relevant threshold.
__label__noRel	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	There were no differences in other treatment-related side effects between groups.
__label__Support	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	Trends observed for the treatment groups were similar.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	Trends observed for the treatment groups were similar.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	Trends observed for the treatment groups were similar.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	Trends observed for the treatment groups were similar.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	Trends observed for the treatment groups were similar.	the change did not meet the clinically relevant threshold.
__label__noRel	Trends observed for the treatment groups were similar.	There were no differences in other treatment-related side effects between groups.
__label__noRel	Trends observed for the treatment groups were similar.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	Trends observed for the treatment groups were similar.
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	the change did not meet the clinically relevant threshold.
__label__noRel	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	There were no differences in other treatment-related side effects between groups.
__label__Support	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	Trends observed for the treatment groups were similar.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	the change did not meet the clinically relevant threshold.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	There were no differences in other treatment-related side effects between groups.
__label__noRel	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	Trends observed for the treatment groups were similar.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	the change did not meet the clinically relevant threshold.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	There were no differences in other treatment-related side effects between groups.
__label__noRel	Although improvements in the UC group occurred by 12-months post-surgery,	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	the change did not meet the clinically relevant threshold.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	the change did not meet the clinically relevant threshold.	Trends observed for the treatment groups were similar.
__label__noRel	the change did not meet the clinically relevant threshold.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	the change did not meet the clinically relevant threshold.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__Attack	the change did not meet the clinically relevant threshold.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	the change did not meet the clinically relevant threshold.	There were no differences in other treatment-related side effects between groups.
__label__noRel	the change did not meet the clinically relevant threshold.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	There were no differences in other treatment-related side effects between groups.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	There were no differences in other treatment-related side effects between groups.	Trends observed for the treatment groups were similar.
__label__noRel	There were no differences in other treatment-related side effects between groups.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	There were no differences in other treatment-related side effects between groups.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	There were no differences in other treatment-related side effects between groups.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	There were no differences in other treatment-related side effects between groups.	the change did not meet the clinically relevant threshold.
__label__noRel	There were no differences in other treatment-related side effects between groups.	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	There were significant (p < 0.05) interaction effects on QoL, fitness and fatigue with differences being observed between the treatment groups and the UC group.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	Trends observed for the treatment groups were similar.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	The treatment groups reported improved QoL, fitness and fatigue over time and changes observed between baseline and post-intervention were clinically relevant.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	In contrast, the UC group experienced no change, or worsening QoL, fitness and fatigue, mid-intervention.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	Although improvements in the UC group occurred by 12-months post-surgery,
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	the change did not meet the clinically relevant threshold.
__label__noRel	This translational intervention trial, delivered either FtF or Tel, supports exercise as a form of adjuvant breast cancer therapy that can prevent declines in fitness and function during treatment and optimise recovery post-treatment.	There were no differences in other treatment-related side effects between groups.
__label__noRel	CRF was significantly reduced in the intervention group, corresponding to a Fatigue score reduction of 3.04 (effect size of 0.44, 95% CI 0.17-0.72) (P = .002), the FACT-An score by 5.40 (P = .015), the FACT-An Toi score by 5.22 (P = .009) and the Anaemia-ANS by 3.76 (P = .002).	There was no statistically significant effect on the General Quality of Life score (FACT-G) or on any of the individual wellbeing scores; Physical (P = .13), Emotional (P = .87), Social (P = .83) and Functional (P = .26).
__label__Support	CRF was significantly reduced in the intervention group, corresponding to a Fatigue score reduction of 3.04 (effect size of 0.44, 95% CI 0.17-0.72) (P = .002), the FACT-An score by 5.40 (P = .015), the FACT-An Toi score by 5.22 (P = .009) and the Anaemia-ANS by 3.76 (P = .002).	In summary, this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy.
__label__noRel	There was no statistically significant effect on the General Quality of Life score (FACT-G) or on any of the individual wellbeing scores; Physical (P = .13), Emotional (P = .87), Social (P = .83) and Functional (P = .26).	CRF was significantly reduced in the intervention group, corresponding to a Fatigue score reduction of 3.04 (effect size of 0.44, 95% CI 0.17-0.72) (P = .002), the FACT-An score by 5.40 (P = .015), the FACT-An Toi score by 5.22 (P = .009) and the Anaemia-ANS by 3.76 (P = .002).
__label__noRel	There was no statistically significant effect on the General Quality of Life score (FACT-G) or on any of the individual wellbeing scores; Physical (P = .13), Emotional (P = .87), Social (P = .83) and Functional (P = .26).	In summary, this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy.
__label__noRel	In summary, this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy.	CRF was significantly reduced in the intervention group, corresponding to a Fatigue score reduction of 3.04 (effect size of 0.44, 95% CI 0.17-0.72) (P = .002), the FACT-An score by 5.40 (P = .015), the FACT-An Toi score by 5.22 (P = .009) and the Anaemia-ANS by 3.76 (P = .002).
__label__noRel	In summary, this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy.	There was no statistically significant effect on the General Quality of Life score (FACT-G) or on any of the individual wellbeing scores; Physical (P = .13), Emotional (P = .87), Social (P = .83) and Functional (P = .26).
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__noRel	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__Attack	This difference was not statistically significant (log-rank test, p=0.818).	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__noRel	This difference was not statistically significant (log-rank test, p=0.818).	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__Support	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__Support	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__Support	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__Support	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__noRel	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__noRel	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__Support	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.
__label__Support	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	The combination of VNR on day 1-8 plus CDDP every 3 weeks may be considered as a reference regimen for the treatment of patients with advanced disease and those who deserve a postoperative therapy, and for future studies.
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	This difference was not statistically significant (log-rank test, p=0.818).
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	Median TTP was 4.5 and 4.6 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one.
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	Median OS was 9.45 and 10 months respectively for weekly VNR/CDDP arm and the day 1-8 VNR/CDDP one without statistically a significant difference (log-rank test, p=0.259).
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	The 1- and 2-year survival rates were 31 and 36%, and 10 and 11% respectively.
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	The incidence of severe neutropenia (34% versus 68%; p=0.0001) and of febrile neutropenia (5% versus 12%; p=0.026), as well as the rate of therapy omissions (10% versus 24%; p=0.0037) were higher in the weekly VNR/CDDP arm than in the day 1-8 VNR/CDDP one.
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	The weekly VNR/CDDP regimen was associated with a lower received dose intensity in a statistically significant fashion (9% versus 22%; p=0.0001) and with a lower non-statistically significant quality of life score as compared to the day 1-8 VNR/CDDP schedule.
__label__noRel	The two schedules are equivalent in terms of overall response rate, median time-to-progression and overall survival.	The combination of day 1-8 VNR plus CDDP every 3 weeks is less toxic and better tolerated than the regimen of weekly VNR plus CDDP every 4 weeks.
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	Global quality of life was similar in both arms,
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	but substantive differences in many symptom scores favored docetaxel.
__label__Support	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	although longer follow-up is required for a definitive statement on survival.
__label__noRel	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	Global quality of life was similar in both arms,
__label__Support	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	although longer follow-up is required for a definitive statement on survival.
__label__noRel	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	Global quality of life was similar in both arms,
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	although longer follow-up is required for a definitive statement on survival.
__label__noRel	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__Attack	although myelosuppression did not influence dose delivery or patient safety.	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	Global quality of life was similar in both arms,
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	although longer follow-up is required for a definitive statement on survival.
__label__noRel	although myelosuppression did not influence dose delivery or patient safety.	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	Global quality of life was similar in both arms,	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	Global quality of life was similar in both arms,	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	Global quality of life was similar in both arms,	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	Global quality of life was similar in both arms,	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	Global quality of life was similar in both arms,	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	Global quality of life was similar in both arms,	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	Global quality of life was similar in both arms,	although longer follow-up is required for a definitive statement on survival.
__label__noRel	Global quality of life was similar in both arms,	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	although myelosuppression did not influence dose delivery or patient safety.
__label__Attack	but substantive differences in many symptom scores favored docetaxel.	Global quality of life was similar in both arms,
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	although longer follow-up is required for a definitive statement on survival.
__label__noRel	but substantive differences in many symptom scores favored docetaxel.	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	Global quality of life was similar in both arms,
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	although longer follow-up is required for a definitive statement on survival.
__label__Support	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	although longer follow-up is required for a definitive statement on survival.	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	although longer follow-up is required for a definitive statement on survival.	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	although longer follow-up is required for a definitive statement on survival.	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	although longer follow-up is required for a definitive statement on survival.	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	although longer follow-up is required for a definitive statement on survival.	Global quality of life was similar in both arms,
__label__noRel	although longer follow-up is required for a definitive statement on survival.	but substantive differences in many symptom scores favored docetaxel.
__label__Attack	although longer follow-up is required for a definitive statement on survival.	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	although longer follow-up is required for a definitive statement on survival.	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	After a median follow-up of 23 months, both groups had similar progression-free survival (medians of 15.0 months for docetaxel-carboplatin and 14.8 months for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, respectively; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, respectively; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, respectively; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	However, docetaxel-carboplatin was associated with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade > or =2 neurosensory toxicity in 11% versus 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade > or =2 neuromotor toxicity in 3% versus 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	Treatment with docetaxel-carboplatin was associated with statistically significantly more grade 3-4 neutropenia (94% versus 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin,
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	although myelosuppression did not influence dose delivery or patient safety.
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	Global quality of life was similar in both arms,
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	but substantive differences in many symptom scores favored docetaxel.
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response,
__label__noRel	Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.	although longer follow-up is required for a definitive statement on survival.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.
__label__noRel	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.
__label__noRel	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__noRel	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.
__label__Support	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	At T3, no significant difference on fatigue was found between CBT and usual care.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	At T3, no significant difference on fatigue was found between CBT and usual care.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	At T3, no significant difference on fatigue was found between CBT and usual care.	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.
__label__noRel	At T3, no significant difference on fatigue was found between CBT and usual care.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__noRel	At T3, no significant difference on fatigue was found between CBT and usual care.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.
__label__Support	At T3, no significant difference on fatigue was found between CBT and usual care.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.
__label__noRel	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.
__label__noRel	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.
__label__Support	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.
__label__noRel	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__Attack	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	No interactions were found between other domains of quality of life, functioning, psychological distress and CBT.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	Fatigue at T2 was predicted by a significant interaction between self-reported cognitive functioning and CBT.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	At T3, no significant difference on fatigue was found between CBT and usual care.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	Exploratory analyses showed that the difference nearly reached significance until 7 months postintervention.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	Patients who experienced more concentration and memory problems at T1 benefited more from CBT for fatigue and are indicators.
__label__noRel	The implication is that CBT for fatigue should be offered to patients with cancer with the highest chance to benefit.	After a year of follow-up, the effect of CBT for fatigue was no longer observed, and the effect on fatigue seemed to be diminished 7 months postintervention.
__label__noRel	There was a trend towards improved global HRQOL during the treatment period.	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,
__label__noRel	There was a trend towards improved global HRQOL during the treatment period.	but the low compliance does not allow to draw definitive conclusions.
__label__noRel	There was a trend towards improved global HRQOL during the treatment period.	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,
__label__noRel	There was a trend towards improved global HRQOL during the treatment period.	but to a limited extent.
__label__Support	There was a trend towards improved global HRQOL during the treatment period.	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
__label__noRel	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,	There was a trend towards improved global HRQOL during the treatment period.
__label__noRel	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,	but the low compliance does not allow to draw definitive conclusions.
__label__noRel	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,
__label__noRel	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,	but to a limited extent.
__label__Support	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
__label__noRel	but the low compliance does not allow to draw definitive conclusions.	There was a trend towards improved global HRQOL during the treatment period.
__label__Attack	but the low compliance does not allow to draw definitive conclusions.	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,
__label__noRel	but the low compliance does not allow to draw definitive conclusions.	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,
__label__noRel	but the low compliance does not allow to draw definitive conclusions.	but to a limited extent.
__label__noRel	but the low compliance does not allow to draw definitive conclusions.	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
__label__noRel	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,	There was a trend towards improved global HRQOL during the treatment period.
__label__noRel	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,
__label__noRel	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,	but the low compliance does not allow to draw definitive conclusions.
__label__noRel	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,	but to a limited extent.
__label__Support	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
__label__noRel	but to a limited extent.	There was a trend towards improved global HRQOL during the treatment period.
__label__noRel	but to a limited extent.	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,
__label__noRel	but to a limited extent.	but the low compliance does not allow to draw definitive conclusions.
__label__Attack	but to a limited extent.	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,
__label__noRel	but to a limited extent.	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
__label__noRel	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.	There was a trend towards improved global HRQOL during the treatment period.
__label__noRel	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.	At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm,
__label__noRel	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.	but the low compliance does not allow to draw definitive conclusions.
__label__noRel	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.	Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2,
__label__noRel	Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.	but to a limited extent.
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__Support	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__Support	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__Support	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__noRel	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy.
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	Among all treatment groups, patients who had a mastectomy had the poorest physical functioning at registration (P<.001) and at enrollment (P=.05).
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	At enrollment, mood and emotional functioning were similar among all patients, with no differences by type of treatment received.
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	At enrollment, symptoms, including muscle stiffness, breast sensitivity, aches and pains, tendency to take naps, and difficulty concentrating, were common among patients in all groups and were statistically significantly associated with poor physical functioning and emotional well-being.
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	Sexual functioning was worse for women who received chemotherapy than for those who did not, regardless of type of surgery (P<.001).
__label__noRel	Clinical interventions to address common symptoms associated with treatment should be considered to improve physical and emotional functioning at the end of primary treatment for breast cancer.	At the end of primary treatment for breast cancer, women in all treatment groups report good emotional functioning but report decreased physical functioning, particularly among women who have a mastectomy or receive chemotherapy.
__label__noRel	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).
__label__noRel	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.
__label__noRel	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.
__label__noRel	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.
__label__noRel	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.	Additional studies are warranted.
__label__noRel	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.
__label__noRel	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.
__label__noRel	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.
__label__noRel	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.
__label__noRel	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).	Additional studies are warranted.
__label__noRel	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.
__label__noRel	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).
__label__noRel	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.
__label__Support	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.
__label__noRel	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.	Additional studies are warranted.
__label__noRel	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.
__label__noRel	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).
__label__noRel	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.
__label__noRel	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.
__label__noRel	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.	Additional studies are warranted.
__label__noRel	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.
__label__noRel	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).
__label__noRel	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.
__label__noRel	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.
__label__Support	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.	Additional studies are warranted.
__label__noRel	Additional studies are warranted.	In a multinational trial of anaemic patients with cancer receiving nonplatinum-containing chemotherapy, epoetin-alfa effectively increased haemoglobin levels, reduced red blood cell transfusion requirements, and improved QOL.
__label__noRel	Additional studies are warranted.	a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126]).
__label__noRel	Additional studies are warranted.	The ICUR for epoetin-alfa treatment was pounds 8,851 per QALY, with a 99% probability of a positive net benefit in QALYs (net benefit = 0.4805 years of perfect life) and a 94% probability of being acceptable using a threshold ICUR of pounds 30,000/QALY.
__label__noRel	Additional studies are warranted.	The main cost drivers distinguishing epoetin-alfa from placebo were the costs of drug and patient care due to increased survival.
__label__noRel	Additional studies are warranted.	The available data suggest a high probability of favourable cost-utility outcomes with epoetin-alfa treatment for anaemia in patients with stage IV breast cancer receiving nonplatinum-containing chemotherapy.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	no other differences in QoL were detected.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	no other differences in QoL were detected.
__label__Support	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	no other differences in QoL were detected.
__label__Support	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	no other differences in QoL were detected.
__label__Support	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	no other differences in QoL were detected.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	no other differences in QoL were detected.
__label__Support	Patients receiving fludarabine had higher scores for social function (P =.008);	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	no other differences in QoL were detected.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	no other differences in QoL were detected.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	no other differences in QoL were detected.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	no other differences in QoL were detected.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	no other differences in QoL were detected.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	no other differences in QoL were detected.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	no other differences in QoL were detected.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	no other differences in QoL were detected.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	but the remaining QL data showed no differences.
__label__Support	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	but the remaining QL data showed no differences.
__label__Support	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	but the remaining QL data showed no differences.
__label__Support	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	but the remaining QL data showed no differences.
__label__Attack	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__Support	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	but the remaining QL data showed no differences.
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	but the remaining QL data showed no differences.
__label__Support	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	but the remaining QL data showed no differences.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	but the remaining QL data showed no differences.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	but the remaining QL data showed no differences.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	but the remaining QL data showed no differences.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	but the remaining QL data showed no differences.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__Attack	but the remaining QL data showed no differences.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	but the remaining QL data showed no differences.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	but the remaining QL data showed no differences.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	but the remaining QL data showed no differences.
__label__noRel	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	Overall response was 54% (95% confidence interval [CI] 44.1%-63.9%) with PVI 5-FU + MMC compared to 38% (95% CI: 28.3%-47.7%) for PVI 5-FU alone (P = 0.024).
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	The median failure free survival was 7.9 months in PVI 5-FU plus MMC and 5.4 months with PVI 5-FU alone (P = 0.033) and at one year 31.9% for the combination compared to 17.7% for PVI 5-FU alone.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	Median survival was 14 months with MMC and 15 months in 5-FU alone; one-year survival 51.7% vs. 57.2%.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	PVI 5-FU + MMC caused more overall haematological toxicity but CTC grades 3/4 was increased only for thrombocytopaenia.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	Two patients treated with a cumulative dose of MMC of 40 mg/m2 developed haemolytic uraemic syndrome warranting the reduction in cumulative MMC dose to 28 mg/m2.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	The global QL scores were better for PVI 5-FU + MMC arm at 24 weeks,
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	but the remaining QL data showed no differences.
__label__noRel	There is no irreversible toxicity with MMC at a cumulative dose of 28 mg/m2.	PVI 5-FU + MMC results in failure-free survival and response advantage, tolerable toxicity and better QL when compared to PVI 5-FU alone but no overall survival advantage.
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__noRel	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__Support	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__noRel	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__Support	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__Support	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__Support	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__noRel	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.
__label__noRel	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	Epoetin alfa administered at 40,000 U once weekly (qw) to anemic cancer patients receiving chemotherapy increases hemoglobin levels, improves quality of life (QOL), and reduces transfusions.
__label__noRel	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	At week 12, Functional Assessment of Cancer Therapy-Anemia (FACT-An; mean, 2.16 +/- 12.84 for epoetin alfa v -4.43 +/- 13.42 for SOC) and FACT-An fatigue (mean, 1.85 +/- 10.52 for epoetin alfa v -3.55 +/- 11.14 for SOC) change scores were significantly higher in the epoetin alfa group (P < .0001).
__label__noRel	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	Hemoglobin responses defined as mean hemoglobin > or = 12 g/dL or a > or = 2 g/dL increase compared with baseline were significantly higher in the epoetin alfa group versus SOC: 52.0% v 5.1% and 65.7% v 6.3%, respectively (P < .0001 for both comparisons).
__label__noRel	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	Percentage transfused was significantly lower in the epoetin alfa group compared with SOC (8.6% v 22.9%).
__label__noRel	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	More than 90% of patients did not require a dose increase and 28.7% had a dose reduction.
__label__Attack	The high effectiveness observed could be attributed in part to early treatment with epoetin alfa.	Epoetin alfa administered at 40,000 U qw is effective in improving QOL, maintaining hemoglobin level, and reducing transfusion requirements in breast cancer patients.
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__noRel	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__Support	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__noRel	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__Support	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__noRel	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__Support	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__Support	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__Support	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__Support	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	For patients with anthracycline-pretreated metastatic breast carcinoma, capecitabine plus docetaxel significantly increased overall survival compared with docetaxel alone.
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	Capecitabine/docetaxel increased the median overall survival by 3 months compared with docetaxel alone (14.5 vs. 11.5 months).
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	The mean quality-adjusted survival was increased by 1.8 months in the capecitabine/docetaxel group.
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	The total medical-resource utilization cost per patient was 8.9% higher with the combination: 24,475 dollars for combination therapy versus 22,477 dollars for single-agent docetaxel.
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	The mean cost per QALY gained with combination therapy was 13,558 dollars (standard deviation, 6742 dollars).
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	Cost savings due to reduced docetaxel dose and hospital use were the major cost offsets with the combination.
__label__noRel	Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies.	Sensitivity analyses showed that varying the mean hospital cost per day from the 5th to the 95th percentile resulted in cost-utility ratios ranging from 20,326 dollars to as low as 6360 dollars.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The results were statistically significant.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The results were statistically significant.
__label__Attack	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The results were statistically significant.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The results were statistically significant.
__label__Attack	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The results were statistically significant.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The results were statistically significant.
__label__Support	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The results were statistically significant.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The results were statistically significant.
__label__Support	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The results were statistically significant.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The results were statistically significant.
__label__Attack	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The results were statistically significant.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The results were statistically significant.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The results were statistically significant.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The results were statistically significant.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__Support	The results were statistically significant.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The results were statistically significant.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The results were statistically significant.	The results were statistically significant.
__label__noRel	The results were statistically significant.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The results were statistically significant.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The results were statistically significant.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The results were statistically significant.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The results were statistically significant.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__Support	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The results were statistically significant.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The results were statistically significant.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The results were statistically significant.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The results were statistically significant.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The results were statistically significant.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The results were statistically significant.	The results were statistically significant.
__label__Support	The results were statistically significant.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The results were statistically significant.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	The results were statistically significant.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The results were statistically significant.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The results were statistically significant.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	The results were statistically significant.
__label__noRel	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__Support	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The results were statistically significant.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The results were statistically significant.
__label__Attack	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The results were statistically significant.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The results were statistically significant.
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same,
__label__noRel	Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.	but the adverse reactions decreased significantly in the PP group compared with those in the GP group.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Support	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	but the study was not designed to detect differences in these parameters.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Support	Other grade 3/4 toxic effects were rare (<5%).	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	but the study was not designed to detect differences in these parameters.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	but the study was not designed to detect differences in these parameters.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Support	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	but the study was not designed to detect differences in these parameters.
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	but the study was not designed to detect differences in these parameters.
__label__Support	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	but the study was not designed to detect differences in these parameters.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	but the study was not designed to detect differences in these parameters.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	but the study was not designed to detect differences in these parameters.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	but the study was not designed to detect differences in these parameters.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	but the study was not designed to detect differences in these parameters.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	but the study was not designed to detect differences in these parameters.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Attack	but the study was not designed to detect differences in these parameters.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	but the study was not designed to detect differences in these parameters.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	but the study was not designed to detect differences in these parameters.
__label__noRel	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	but this finding was inconsistent across different methods of analysis.
__label__noRel	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__noRel	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__Support	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__noRel	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	but this finding was inconsistent across different methods of analysis.
__label__noRel	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__noRel	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__Support	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	but this finding was inconsistent across different methods of analysis.	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__Attack	but this finding was inconsistent across different methods of analysis.	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	but this finding was inconsistent across different methods of analysis.	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	but this finding was inconsistent across different methods of analysis.	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__noRel	but this finding was inconsistent across different methods of analysis.	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__noRel	but this finding was inconsistent across different methods of analysis.	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__noRel	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	but this finding was inconsistent across different methods of analysis.
__label__noRel	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__noRel	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__Support	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__noRel	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	but this finding was inconsistent across different methods of analysis.
__label__noRel	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__Support	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__noRel	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	but this finding was inconsistent across different methods of analysis.
__label__noRel	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__Support	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	There were no significant group differences in global QoL, pain or fatigue up to 26 weeks.
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	The dyspnoea palliation rate was lower in the C3 arm at 18 and 26 weeks (P<0.05),
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	but this finding was inconsistent across different methods of analysis.
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	Median survival in the C3 group was 28 vs 32 weeks in the C6 group (P=0.75, HR 1.04, 95% CI 0.82-1.31).
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	One- and 2-year survival rates were 25 and 9% vs 25 and 5% in the C3 and C6 arm, respectively.
__label__noRel	In conclusion, palliative chemotherapy with carboplatin and vinorelbine beyond three courses conveys no survival or consistent QoL benefits in advanced NSCLC.	Median progression-free survival was 16 and 21 weeks in the C3 and C6 groups, respectively (P=0.21, HR 0.86, 95% CI 0.68-1.08).
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	There were no opportunistic infections.
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	There were no opportunistic infections.
__label__noRel	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__Support	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	There were no opportunistic infections.
__label__noRel	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__Support	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	There were no opportunistic infections.
__label__Support	There were no opportunistic infections.	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__noRel	There were no opportunistic infections.	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	There were no opportunistic infections.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	There were no opportunistic infections.	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__Support	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__noRel	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.
__label__noRel	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.
__label__noRel	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).	The secondary endpoints were also not significantly different between the arms.
__label__noRel	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).
__label__Support	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.
__label__noRel	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.	The secondary endpoints were also not significantly different between the arms.
__label__noRel	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).
__label__noRel	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.
__label__noRel	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.	The secondary endpoints were also not significantly different between the arms.
__label__noRel	The secondary endpoints were also not significantly different between the arms.	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).
__label__noRel	The secondary endpoints were also not significantly different between the arms.	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.
__label__Support	The secondary endpoints were also not significantly different between the arms.	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Toxicity was mild in both arms.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	QOL analyses favored Arm A.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Toxicity was mild in both arms.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	QOL analyses favored Arm A.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Toxicity was mild in both arms.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	QOL analyses favored Arm A.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Toxicity was mild in both arms.
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	QOL analyses favored Arm A.
__label__Support	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Toxicity was mild in both arms.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	QOL analyses favored Arm A.
__label__Support	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Toxicity was mild in both arms.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Toxicity was mild in both arms.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Toxicity was mild in both arms.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Toxicity was mild in both arms.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Toxicity was mild in both arms.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Toxicity was mild in both arms.	QOL analyses favored Arm A.
__label__Support	Toxicity was mild in both arms.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	QOL analyses favored Arm A.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	QOL analyses favored Arm A.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	QOL analyses favored Arm A.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	QOL analyses favored Arm A.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	QOL analyses favored Arm A.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	QOL analyses favored Arm A.	Toxicity was mild in both arms.
__label__Support	QOL analyses favored Arm A.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Toxicity was mild in both arms.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	QOL analyses favored Arm A.
__label__noRel	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.
__label__noRel	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;
__label__noRel	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.
__label__noRel	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;
__label__noRel	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.
__label__noRel	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;
__label__noRel	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.
__label__noRel	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;
__label__noRel	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.
__label__Support	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.
__label__noRel	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.
__label__noRel	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;
__label__noRel	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.
__label__Support	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.
__label__noRel	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;
__label__noRel	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;
__label__noRel	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;	Adverse events in both groups included fatigue, diminished sexual function, and hot flushes.
__label__Support	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;	The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer.
__label__noRel	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;	After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died;
__label__noRel	The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively;	the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group.
__label__noRel	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).
__label__noRel	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.
__label__noRel	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.
__label__Support	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.
__label__noRel	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time × arm' interaction, indicating a persistent better patient perspective with MPT treatment.
__label__noRel	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.
__label__noRel	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.
__label__noRel	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.
__label__Support	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.
__label__noRel	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time × arm' interaction, indicating a persistent better patient perspective with MPT treatment.
__label__noRel	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.
__label__noRel	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).
__label__noRel	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.
__label__Support	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.
__label__noRel	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time × arm' interaction, indicating a persistent better patient perspective with MPT treatment.
__label__noRel	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.
__label__noRel	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).
__label__noRel	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.
__label__Support	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.
__label__noRel	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time × arm' interaction, indicating a persistent better patient perspective with MPT treatment.
__label__noRel	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.
__label__noRel	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).
__label__noRel	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.
__label__noRel	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.
__label__noRel	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time × arm' interaction, indicating a persistent better patient perspective with MPT treatment.
__label__noRel	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time × arm' interaction, indicating a persistent better patient perspective with MPT treatment.	The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the MP arm.
__label__noRel	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time × arm' interaction, indicating a persistent better patient perspective with MPT treatment.	During thalidomide maintenance, the scores for the QLQ-MY24 paraesthesia became significantly higher in the MPT arm (P<0.001).
__label__noRel	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time × arm' interaction, indicating a persistent better patient perspective with MPT treatment.	The QLQ-C30 subscales pain (P=0.12), insomnia (P=0.068), appetite loss (P=0.074) and the QLQ-MY24 item sick (P=0.086) scored marginally better during thalidomide maintenance.
__label__noRel	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time × arm' interaction, indicating a persistent better patient perspective with MPT treatment.	The overall QoL-scale QLQ-C30-HRQoL showed a significant time trend towards more favourable mean values during protocol treatment without differences between MP and MPT.
__label__Support	For the QLQ-C30 subscales emotional function and future perspectives, difference in favour of the MPT arm from the start of treatment was observed (P=0.018 and P=0.045, respectively) with no significant 'time × arm' interaction, indicating a persistent better patient perspective with MPT treatment.	This study shows that the higher frequency of toxicity associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective.
__label__noRel	There was no differences in acute toxicities between the 2 groups.	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	There was no differences in acute toxicities between the 2 groups.	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	There was no differences in acute toxicities between the 2 groups.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	There was no differences in acute toxicities between the 2 groups.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	There was no differences in acute toxicities between the 2 groups.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	There was no differences in acute toxicities between the 2 groups.	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	There was no differences in acute toxicities between the 2 groups.	Both groups showed an increase in symptom and interference scores,
__label__noRel	There was no differences in acute toxicities between the 2 groups.	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	There was no differences in acute toxicities between the 2 groups.	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	There was no differences in acute toxicities between the 2 groups.
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	Both groups showed an increase in symptom and interference scores,
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	There was no differences in acute toxicities between the 2 groups.
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	Both groups showed an increase in symptom and interference scores,
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	There was no differences in acute toxicities between the 2 groups.
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__Support	The rhDNase group showed no change in OPS-DNA concentration,	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	Both groups showed an increase in symptom and interference scores,
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	The rhDNase group showed no change in OPS-DNA concentration,	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	There was no differences in acute toxicities between the 2 groups.
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__Support	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	Both groups showed an increase in symptom and interference scores,
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	There was no differences in acute toxicities between the 2 groups.
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__Support	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	Both groups showed an increase in symptom and interference scores,
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	There was no differences in acute toxicities between the 2 groups.
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	Both groups showed an increase in symptom and interference scores,
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	Both groups showed an increase in symptom and interference scores,	There was no differences in acute toxicities between the 2 groups.
__label__noRel	Both groups showed an increase in symptom and interference scores,	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	Both groups showed an increase in symptom and interference scores,	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	Both groups showed an increase in symptom and interference scores,	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	Both groups showed an increase in symptom and interference scores,	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	Both groups showed an increase in symptom and interference scores,	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	Both groups showed an increase in symptom and interference scores,	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	Both groups showed an increase in symptom and interference scores,	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	Both groups showed an increase in symptom and interference scores,	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	There was no differences in acute toxicities between the 2 groups.
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__Attack	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	Both groups showed an increase in symptom and interference scores,
__label__noRel	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.	There were no statistically significant differences in patients' QOL outcomes over the study period.
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	There was no differences in acute toxicities between the 2 groups.
__label__Support	There were no statistically significant differences in patients' QOL outcomes over the study period.	Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group.
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT.
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	The rhDNase group showed no change in OPS-DNA concentration,
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	the placebo group showed a significant increase in DNA concentration during the drug trial (P=.045).
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	Patients in the rhDNase group exhibited significant clinical improvement in OPS, blindly assessed by a physician, compared with the placebo group (67% vs 27%, respectively; P=.046).
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	Similarly, both groups showed a decline in physical and functional well being but recovered in the 3 months posttreatment follow-up, with the rhDNase group exhibiting speedier recovery.
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	Both groups showed an increase in symptom and interference scores,
__label__noRel	There were no statistically significant differences in patients' QOL outcomes over the study period.	patients in the rhDNase group showed a greater decline in both scores during the 3 months posttreatment.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__Support	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Attack	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.
__label__noRel	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.
__label__noRel	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),
__label__noRel	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
__label__Support	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
__label__noRel	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).
__label__noRel	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.
__label__noRel	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),
__label__noRel	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
__label__Support	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
__label__noRel	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).
__label__noRel	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.
__label__noRel	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),
__label__noRel	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
__label__Support	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
__label__noRel	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).
__label__noRel	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.
__label__noRel	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.
__label__noRel	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
__label__Support	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
__label__noRel	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).
__label__noRel	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.
__label__noRel	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.
__label__noRel	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),
__label__noRel	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
__label__noRel	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.	Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001).
__label__noRel	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.	Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved.
__label__noRel	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.	Of the 41 patients who reported swelling at baseline, 38 (93%) improved.
__label__noRel	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.	Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75),
__label__noRel	Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.	but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	VC, GC, and TC are not superior to PC in terms of overall survival (OS).	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	However, the trend in RR, PFS, and OS favors PC.	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__Attack	However, the trend in RR, PFS, and OS favors PC.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	However, the trend in RR, PFS, and OS favors PC.	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	However, the trend in RR, PFS, and OS favors PC.	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	However, the trend in RR, PFS, and OS favors PC.	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	However, the trend in RR, PFS, and OS favors PC.	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__Support	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__Support	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__Support	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.
__label__noRel	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.
__label__Support	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	VC, GC, and TC are not superior to PC in terms of overall survival (OS).
__label__noRel	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	However, the trend in RR, PFS, and OS favors PC.
__label__noRel	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia.
__label__noRel	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively.
__label__noRel	The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC.	The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC.
__label__noRel	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.	No myomectomy cases had further intervention.
__label__noRel	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.	No myomectomy cases had further intervention.
__label__noRel	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	No myomectomy cases had further intervention.
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__Support	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	No myomectomy cases had further intervention.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__Support	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).	New fibroid formation is significantly higher after myomectomy.
__label__noRel	No myomectomy cases had further intervention.	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	No myomectomy cases had further intervention.	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	No myomectomy cases had further intervention.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	No myomectomy cases had further intervention.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	No myomectomy cases had further intervention.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	No myomectomy cases had further intervention.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	No myomectomy cases had further intervention.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	No myomectomy cases had further intervention.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	No myomectomy cases had further intervention.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__Support	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).	New fibroid formation is significantly higher after myomectomy.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	No myomectomy cases had further intervention.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	No myomectomy cases had further intervention.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.	New fibroid formation is significantly higher after myomectomy.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	In the UAE group, mean ± standard deviation uterine volume was 670 ± 503, 422 ± 353, and 292 ± 287 mL at baseline, 6 months, and 5 years, respectively.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	Mean dominant fibroid diameter was 7.6 ± 3.0, 5.8 ± 2.9, and 5 ± 2.9 cm at baseline, 6 months, and 5 years.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	Fibroid infarction at 6 months was complete in 35 % of women, almost complete in 29 %, and partial in 36 %.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	Need for reintervention was 19, 10, and 33 % in these groups, respectively (p = 0.123).
__label__noRel	New fibroid formation is significantly higher after myomectomy.	No myomectomy cases had further intervention.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	At 5 years, the prevalence of new fibroid was 60 % in the myomectomy group and 7 % in the UAE group (p = 0.008).
__label__noRel	New fibroid formation is significantly higher after myomectomy.	There is a further significant reduction in both uterine volume and dominant fibroid diameter between 6 months and 5 years after UAE.
__label__noRel	New fibroid formation is significantly higher after myomectomy.	Complete fibroid infarction does not translate into total freedom from a subsequent reintervention.
__label__noRel	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__Support	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__noRel	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__Support	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__noRel	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__noRel	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__noRel	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__Support	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	For BT versus RP, there was no difference in bowel or hormonal domains,	men treated with BT scored better in urinary (91.8 v 88.1; P = .02) and sexual (52.5 v 39.2; P = .001) domains, and in patient satisfaction (93.6 v 76.9; P < .001).
__label__Support	For BT versus RP, there was no difference in bowel or hormonal domains,	HRQOL evaluated 3.2 to 6.5 years after treatment showed an advantage for BT in urinary and sexual domains and in patient satisfaction.
__label__noRel	men treated with BT scored better in urinary (91.8 v 88.1; P = .02) and sexual (52.5 v 39.2; P = .001) domains, and in patient satisfaction (93.6 v 76.9; P < .001).	For BT versus RP, there was no difference in bowel or hormonal domains,
__label__Support	men treated with BT scored better in urinary (91.8 v 88.1; P = .02) and sexual (52.5 v 39.2; P = .001) domains, and in patient satisfaction (93.6 v 76.9; P < .001).	HRQOL evaluated 3.2 to 6.5 years after treatment showed an advantage for BT in urinary and sexual domains and in patient satisfaction.
__label__noRel	HRQOL evaluated 3.2 to 6.5 years after treatment showed an advantage for BT in urinary and sexual domains and in patient satisfaction.	For BT versus RP, there was no difference in bowel or hormonal domains,
__label__noRel	HRQOL evaluated 3.2 to 6.5 years after treatment showed an advantage for BT in urinary and sexual domains and in patient satisfaction.	men treated with BT scored better in urinary (91.8 v 88.1; P = .02) and sexual (52.5 v 39.2; P = .001) domains, and in patient satisfaction (93.6 v 76.9; P < .001).
__label__noRel	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.
__label__noRel	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).
__label__noRel	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).
__label__Support	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.
__label__noRel	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).
__label__noRel	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).
__label__Support	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.
__label__noRel	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.
__label__noRel	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).
__label__Support	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.
__label__noRel	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.
__label__noRel	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).
__label__noRel	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	Risk for distress accounted for very few moderation effects.
__label__noRel	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	but few sustained effects.
__label__Support	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	Risk for distress accounted for very few moderation effects.	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	Risk for distress accounted for very few moderation effects.	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	Risk for distress accounted for very few moderation effects.	but few sustained effects.
__label__noRel	Risk for distress accounted for very few moderation effects.	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	Risk for distress accounted for very few moderation effects.
__label__noRel	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	but few sustained effects.
__label__Support	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	but few sustained effects.	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	but few sustained effects.	Risk for distress accounted for very few moderation effects.
__label__Attack	but few sustained effects.	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	but few sustained effects.	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	Risk for distress accounted for very few moderation effects.
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	but few sustained effects.
__label__noRel	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3	but at a slower rate for the experimental group (p = 0.02).
__label__noRel	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).
__label__noRel	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.
__label__Support	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.
__label__Attack	but at a slower rate for the experimental group (p = 0.02).	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3
__label__noRel	but at a slower rate for the experimental group (p = 0.02).	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).
__label__noRel	but at a slower rate for the experimental group (p = 0.02).	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.
__label__noRel	but at a slower rate for the experimental group (p = 0.02).	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.
__label__noRel	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3
__label__noRel	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).	but at a slower rate for the experimental group (p = 0.02).
__label__noRel	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.
__label__Support	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.
__label__noRel	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3
__label__noRel	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.	but at a slower rate for the experimental group (p = 0.02).
__label__noRel	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).
__label__Support	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.
__label__noRel	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.	With a mixed modeling approach, total FACIT F scores for the entire sample declined at a significant rate (p = 0.003) beginning with cycle 3
__label__noRel	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.	but at a slower rate for the experimental group (p = 0.02).
__label__noRel	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.	Fatigue scores indicated less increase and physical well-being subscale scores showed less decline for the experimental group (p = 0.008 and p = 0.02, respectively).
__label__noRel	Seated exercise may be a feasible exercise program for women with advanced cancer for controlling fatigue and improving physical well-being.	Women with advanced breast cancer randomized to the seated exercise intervention had a slower decline in total and physical well-being and less increase in fatigue scores starting with the third cycle of chemotherapy.
__label__Support	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.
__label__noRel	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.	PIDs were 0·9 and 0·3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0·001), and 1·5 and 0·3 respectively on day 3 (P < 0·001).
__label__noRel	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0·001).
__label__noRel	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.	The SF-6D score decreased to 21·2 ± 2·5 in the oxycodone/paracetamol group at the end of the phase (P = 0·001).
__label__noRel	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.
__label__noRel	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.	PIDs were 0·9 and 0·3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0·001), and 1·5 and 0·3 respectively on day 3 (P < 0·001).
__label__noRel	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0·001).
__label__noRel	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.	The SF-6D score decreased to 21·2 ± 2·5 in the oxycodone/paracetamol group at the end of the phase (P = 0·001).
__label__noRel	PIDs were 0·9 and 0·3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0·001), and 1·5 and 0·3 respectively on day 3 (P < 0·001).	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.
__label__Support	PIDs were 0·9 and 0·3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0·001), and 1·5 and 0·3 respectively on day 3 (P < 0·001).	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.
__label__noRel	PIDs were 0·9 and 0·3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0·001), and 1·5 and 0·3 respectively on day 3 (P < 0·001).	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0·001).
__label__noRel	PIDs were 0·9 and 0·3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0·001), and 1·5 and 0·3 respectively on day 3 (P < 0·001).	The SF-6D score decreased to 21·2 ± 2·5 in the oxycodone/paracetamol group at the end of the phase (P = 0·001).
__label__noRel	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0·001).	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.
__label__Attack	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0·001).	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.
__label__noRel	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0·001).	PIDs were 0·9 and 0·3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0·001), and 1·5 and 0·3 respectively on day 3 (P < 0·001).
__label__noRel	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0·001).	The SF-6D score decreased to 21·2 ± 2·5 in the oxycodone/paracetamol group at the end of the phase (P = 0·001).
__label__noRel	The SF-6D score decreased to 21·2 ± 2·5 in the oxycodone/paracetamol group at the end of the phase (P = 0·001).	In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.
__label__Support	The SF-6D score decreased to 21·2 ± 2·5 in the oxycodone/paracetamol group at the end of the phase (P = 0·001).	Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.
__label__noRel	The SF-6D score decreased to 21·2 ± 2·5 in the oxycodone/paracetamol group at the end of the phase (P = 0·001).	PIDs were 0·9 and 0·3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0·001), and 1·5 and 0·3 respectively on day 3 (P < 0·001).
__label__noRel	The SF-6D score decreased to 21·2 ± 2·5 in the oxycodone/paracetamol group at the end of the phase (P = 0·001).	Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0·001).
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	No unique safety observations were reported during open-label exposure.
__label__noRel	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	No unique safety observations were reported during open-label exposure.
__label__noRel	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	No unique safety observations were reported during open-label exposure.
__label__noRel	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	No unique safety observations were reported during open-label exposure.
__label__noRel	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	No unique safety observations were reported during open-label exposure.
__label__noRel	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	No unique safety observations were reported during open-label exposure.	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	No unique safety observations were reported during open-label exposure.	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	No unique safety observations were reported during open-label exposure.	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	No unique safety observations were reported during open-label exposure.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	No unique safety observations were reported during open-label exposure.	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	No unique safety observations were reported during open-label exposure.	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
__label__noRel	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.	No unique safety observations were reported during open-label exposure.
__label__noRel	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__noRel	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__Support	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__noRel	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__Support	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__noRel	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	HRQOL changes within chemotherapy response strata revealed stable index scores	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	HRQOL changes within chemotherapy response strata revealed stable index scores	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__noRel	HRQOL changes within chemotherapy response strata revealed stable index scores	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	HRQOL changes within chemotherapy response strata revealed stable index scores	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__Support	HRQOL changes within chemotherapy response strata revealed stable index scores	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__noRel	HRQOL changes within chemotherapy response strata revealed stable index scores	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__Attack	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__noRel	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__noRel	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__noRel	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__Support	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__noRel	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	A small decline in visual analogue scale scores was observed (70.7 vs. 68.2, P=0.026).
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	Mean index scores remained stable (0.78 at baseline [n=267], 0.79 at eight weeks [n=186], P=0.34, Wilcoxon signed rank test), attributable to a modest deterioration of physical function domain scores coincident with small improvements in pain and anxiety/depression scores.
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	HRQOL changes within chemotherapy response strata revealed stable index scores
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	but a trend of worsened physical function among patients with disease progression compared with those with stable or improved disease.
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	Visual analogue scale scores trended downward over time irrespective of chemotherapy response status, with a statistically meaningful deterioration in patients who progressed (68.9 vs. 64.4, P=0.029).
__label__noRel	Those who respond to gemcitabine may experience a slight slowing of functional deterioration.	Response to gemcitabine treatment in APC is not associated with appreciable improvement of global HRQOL.
__label__noRel	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__noRel	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__Support	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__noRel	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__Support	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__Support	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__noRel	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__Support	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	The most common treatment-related adverse events were rash, diarrhea and pruritus.	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	The most common treatment-related adverse events were rash, diarrhea and pruritus.	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	The most common treatment-related adverse events were rash, diarrhea and pruritus.	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__Support	The most common treatment-related adverse events were rash, diarrhea and pruritus.	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	The most common treatment-related adverse events were rash, diarrhea and pruritus.	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	The most common treatment-related adverse events were rash, diarrhea and pruritus.	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__noRel	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__Support	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	PFS was significantly prolonged in the erlotinib treatment arm, both overall (hazard ratio [HR]: 0.57; p=0.0067) and in patients with EGFR IHC-positive disease (HR=0.50; p=0.0057).
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	There was a trend towards an increase in OS, which reached statistical significance in the EGFR IHC-positive subgroup (p=0.0233).
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	The overall response rate was significantly higher with erlotinib compared with placebo (24% versus 5%; p=0.0025).
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	Erlotinib was generally well tolerated and had no negative impact on QoL in this subpopulation.
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	The most common treatment-related adverse events were rash, diarrhea and pruritus.
__label__noRel	Maintenance treatment with erlotinib appears to be a useful option for the management of Asian patients with advanced NSCLC without progression after first-line chemotherapy.	Erlotinib was effective and well tolerated in Asian patients, producing benefits consistent with those observed in the overall SATURN population.
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__Support	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.	although the regimen generally was well tolerated.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).	although the regimen generally was well tolerated.
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__Support	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.	although the regimen generally was well tolerated.
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__Support	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.	although the regimen generally was well tolerated.
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.	although the regimen generally was well tolerated.
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.	although the regimen generally was well tolerated.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__noRel	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,	although the regimen generally was well tolerated.
__label__noRel	although the regimen generally was well tolerated.	The ORRs were 48.9% (95% confidence interval [CI], 38.5%-59.5%) and 58.7% (95% CI, 47.9%-68.9%; P = .117) with PB and PB+G, respectively.
__label__noRel	although the regimen generally was well tolerated.	The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC).
__label__noRel	although the regimen generally was well tolerated.	The median PFS was 8.8 months (95% CI, 8.1-10.4 months) and 11.3 months (95% CI, 9.7-12.7 months; P = .247; hazard ratio, 0.82); the median OS was 25.0 months (95% CI, 18.8-not assessable [N/A] months) and 24.3 months (95% CI, 20.3-N/A months; P = .475; hazard ratio, 0.84), with PB and PB+G, respectively.
__label__noRel	although the regimen generally was well tolerated.	There was significantly more grade 3-4 neutropenia (P = .001) and dyspnea (P = .014) with PB+G.
__label__noRel	although the regimen generally was well tolerated.	Patients treated with PB experienced more improvement in total FACT-B (Functional Assessment of Cancer Therapy-Breast) (P = .021), FACT-B Social/Family Well-being (P = .041), and Breast Cancer-Additional Concerns (P = .008) scores than patients treated with PB+G.
__label__noRel	although the regimen generally was well tolerated.	The addition of gemcitabine to PB was not associated with a statistically significant improvement in ORR.
__label__Attack	although the regimen generally was well tolerated.	Treatment with PB+G increased the incidence of severe neutropenia and dyspnea,
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	Patients with dysuria had a statistically higher IPSS.
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	The dysuria resolved faster in patients implanted with 103Pd
__label__noRel	The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months.	In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores,
